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Abstract
Background: Data collection consumes a large proportion of clinical trial resources. Each data item requires time
and effort for collection, processing and quality control procedures. In general, more data equals a heavier burden
for trial staff and participants. It is also likely to increase costs. Knowing the types of data being collected, and in
what proportion, will be helpful to ensure that limited trial resources and participant goodwill are used wisely.
Aim: The aim of this study is to categorise the types of data collected across a broad range of trials and assess
what proportion of collected data each category represents.
Methods: We developed a standard operating procedure to categorise data into primary outcome, secondary
outcome and 15 other categories. We categorised all variables collected on trial data collection forms from 18,
mainly publicly funded, randomised superiority trials, including trials of an investigational medicinal product and
complex interventions. Categorisation was done independently in pairs: one person having in-depth knowledge of
the trial, the other independent of the trial. Disagreement was resolved through reference to the trial protocol and
discussion, with the project team being consulted if necessary.
Key results: Primary outcome data accounted for 5.0% (median)/11.2% (mean) of all data items collected.
Secondary outcomes accounted for 39.9% (median)/42.5% (mean) of all data items. Non-outcome data such as
participant identifiers and demographic data represented 32.4% (median)/36.5% (mean) of all data items collected.
Conclusion: A small proportion of the data collected in our sample of 18 trials was related to the primary outcome.
Secondary outcomes accounted for eight times the volume of data as the primary outcome. A substantial amount
of data collection is not related to trial outcomes. Trialists should work to make sure that the data they collect are
only those essential to support the health and treatment decisions of those whom the trial is designed to inform.
Introduction
Data collection consumes a large proportion of trial re-
sources. Each data item requires time and effort for col-
lection, processing and quality control procedures [1].
Generally speaking, more data equals a heavier burden
for trial staff and participants. More data may also in-
crease the cost of the trial.
Outcomes are also not created equal. Trials usually
have one outcome that is considered primary—the out-
come of highest importance in the trial. Ideally, this out-
come should be of most interest to stakeholders such as
patients, clinicians, policymakers and funders. The pri-
mary outcome is normally the outcome used in the
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sample size calculation [2]. However, it is rare for a sin-
gle outcome to provide enough information about the
trial intervention(s) on its own, so it is usual to have sec-
ondary outcomes to provide a wider context for the
main research question. These outcomes will be detailed
in the trial protocol but tend not to drive sample size be-
cause they are rarely included in sample size
calculations.
An under-recognised challenge in conducting a clinical
trial is ensuring that the data collected are sufficient to
answer the trial research questions but are not so sub-
stantial as to threaten the feasibility of the trial. As the
primary outcome is the measurement that will be used
to evaluate the effectiveness of the intervention, it seems
reasonable to expect that it will receive a substantial part
of the data collection effort (and funding). It is not clear
that this is currently the case.
Data collection covers more than outcomes. Trials col-
lect demographic, medical history, safety and regulatory
non-outcome data, as well as generating their own data
in the form of identifiers and process checks (e.g. ‘was
leaflet X handed out? Y/N’). For drug trials in particular,
evaluations may be focused on differentiating similar,
competing therapies by incremental differences in one
or all of safety, efficacy [3] and health economic mea-
sures, which can require a substantial amount of data.
Growing requirements and requests from regulators and
sponsor organisations have also increased the amount of
data that routinely needs to be collected in clinical trials
[3–5]. The amount of secondary, exploratory and auxil-
iary data in trials can be substantial, with more than half
of the outcome data collected for Phase II and Phase III
trials being less essential or supplementary [3]. One
study of six drug/nutritional supplement trials found
137,008 items of data for 126 participants, of which the
authors considered only 18,124 to be key for targeted
risk-based monitoring purposes, or just 13% of all data
collected [6].
Trials are collecting more data than ever. Getz and
colleagues [7] examined 9737 trial protocols of Phase II
and Phase III trials and found that between two time pe-
riods (2000–2005 and 2011–2015) the number of
planned study visits had increased by 23% (Phase II) and
25% (Phase III). Similarly, the total number of trial pro-
cedures had also increased by 67% and 70%, respectively.
Both increased data collection requirements. Apart from
extra workload, these increases can also adversely affect
recruitment and retention rates [7–9]. ‘How can trials be
designed to minimise burden on staff and participants
and how does this affect retention?’ was ranked third in
a recent prioritisation exercise of unanswered research
questions on trial retention [10]. Collecting large
amounts of data may also increase missing data. This
will reduce the power of the study if it affects the
primary outcome and will reduce the power of already
potentially underpowered secondary outcome analyses,
especially if the data arenot missing at random [11].
Added to this is the possibility that after doing a lot of
work, the data are not used anyway. O’Leary et al. [12]
found that large proportions of collected data (median
82%, range 73–89%) were not reported in associated
publications.
We wanted to examine the type and volume of data
being collected across a variety of clinical trial types.
This paper describes work done in the DataCat project
in which we (1) developed a list of categories of data col-
lected in trials and (2) applied that categorisation system
to the data collected in trials run in the UK and Ireland.
The work was unfunded and done as part of the Trial
Forge initiative (www.trialforge.org) to improve trial
efficiency.
Methods
The original idea for this project came from a workshop
held at the annual meeting of the UK Trial Managers’
Network (UKTMN) in London, UK, on 10th September
2015. ST facilitated the workshop, and around 20 trial
managers suggested, then ranked, ideas for research pro-
jects addressing important questions relevant to them.
The question ‘Why do we collect the data we do: what is
the purpose of the data we collect on the CRF (case re-
port form) and do we actually use it?’ was ranked second
and formed the basis of the work done here. (The top
ranked question, about electronic versus paper data col-
lection, was considered more difficult to study without
funding.) The work described here addresses the first
half of the question, i.e. ‘What is the purpose of the data
we collect on the CRF?’
Shortly after the meeting, we formed a group, mainly
composed of trial managers but also trial methodolo-
gists, interested in addressing this question; many had
attended the London workshop. Over time we expanded
the group slightly to include people not present at the
workshop, including the addition of a trial data manager.
The work had three stages:
 We developed a standard operating procedure for
categorising data.
 We piloted the categories.
 We applied the tested categorisation list to a larger
sample of trials.
Stage I: development of a standard operating procedure
for data categorisation
We developed the list of categories iteratively through a
series of teleconference discussions where potential
categories of data were considered. We drew the data
categories from general features of trial protocols (e.g.
Crowley et al. Trials          (2020) 21:535 Page 2 of 10
demographics, primary outcomes, secondary outcomes),
our experience of running trials (e.g. data required to
identify participants or link data) and our experience of
initial attempts to apply the list to trial data collection
forms (case report forms [CRFs] and participant ques-
tionnaires) from three trials (AMBER [13], KAT [14]
and SALVO [15]). We identified these trials primarily
from personal involvement with the trial; none was a
Clinical Trial of an Investigational Medicinal Product
(CTIMP). We were interested in definitive trials, often
called Phase III trials. Based on this, a standard operat-
ing procedure (SOP) was developed for how to categor-
ise the data (see Additional file 1).
Stage II: piloting of the categories
We piloted the categorisation list and SOP with six
trials, including the three with which we developed
the process. The three additional trials were also se-
lected based on personal involvement in the trial; we
quickly found in Stage I that categorisation needed
someone close to the trial. We first listed all the data
items collected on the trial data collection forms. We
defined data items as the individual pieces of data
collected on the trial data collection forms (also
called fields or variables). We then assigned each data
item on the list to a single data category that best de-
scribed what type of data it was (i.e. the main reason
it was collected). We used the trial protocol to help
with this process. Where data items were dependent
on events occurring (e.g. repeat visits, an adverse
event, drug prescription), the number of data items
categorised did not necessarily represent the max-
imum possible number. Two team members inde-
pendently categorised the data for each trial, one who
was familiar with the trial and one who was not. The
two reviewers then met or had a telephone call to
discuss and resolve any discrepancies in their categor-
isations. Some data items were hard to categorise,
and discrepancies often involved one of the two re-
viewers using ‘Miscellaneous’ where the other did not.
For example, in SALVO [15] ‘Mother ABO blood
group’ was initially categorised as ‘Miscellaneous’ by
one person and ‘Medical history’ by the other. After
discussion the two team members agreed that in this
case this data item was best described as ‘Miscellan-
eous’. If necessary, the rest of the project team was
consulted to resolve a discrepancy.
Having piloted the categorisation list, a new member
of the project team (EC) reviewed the same six trials and
all sources of discrepancy together with one member of
the project team (ST). We refined the categories list and
guidance where necessary with agreement from the
whole group.
Stage III: application of the tested categorisation list to a
larger sample of trials
We then categorised data items collected in an add-
itional sample of 12 trials (also a convenience sample)
using the categorisation list and SOP. As with the pilot,
we identified the trials primarily through the personal
knowledge of the trial by a project team member. In this
final stage we included CTIMPs along with additional
non-CTIMPs.
Results
Stages I and II (creating the categorisation list, standard
operating procedure and piloting)
The final list of categories included 17 types of data
(Table 1) together with guidance on the type of data
each category might contain. This included a hierarch-
ical categorisation process which was developed to han-
dle situations where a data item could potentially be
placed into more than one category (see Additional file
1 for the guidance document we used when making cat-
egory decisions).
The review of the six pilot trials led by EC resulted in
one new category (‘Primary outcome but not primary
analysis’) and some additional guidance to reduce ambi-
guity around category choice. The extra category was
added to account for cases where the primary outcome
(e.g. weight) was measured but at a timepoint (e.g. 12
weeks) that was not the primary outcome measurement
point (e.g. 12 months). The SOP was also updated (see
Additional file 1).
3.2. Stage III
A total of 18 trials were categorised, including the six
used in the pilot; 15 complex intervention non-CTIMPs
and three CTIMPs, predominantly publicly funded and
sponsored by UK academic and/or National Health Ser-
vice (NHS) institutions. All trials were superiority trials.
The 18 trials had different chief investigators, and the
teams were either completely, or largely, different. There
was some overlap of individuals (e.g. ST was involved in
ActWELL and ECLS; EAGLE and TAGS involved some
of the same clinicians), but the majority of the trial team
were different across all 18 trials. The oldest began in
1998 with the most recent beginning in 2017. The char-
acteristics of the included trials are presented in Table 2.
Duration of follow-up ranged from a few days (until dis-
charge) to 10–15 years, and target sample sizes ranged
from 40 to 12,000 trial participants. Trial data collection
documents were received from five different institutions
in the UK and Ireland.
Proportions of data items within each trial were calcu-
lated and those proportions summarised across all 18
trials. Table 3 presents these categorisation results. Pri-
mary outcome data accounted for 5.0% (median)/11.2%
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(mean) of all data items collected. Secondary outcomes
constituted the largest proportion of data items collected
per participant per trial summarised across all included
trials (median 39.9%; mean 42.5%). Two trials are not-
able exceptions to this trend (see Table 2): in ViDiFlu (a
National Institute for Health Research [NIHR]
programme grant-funded trial of vitamin D for preven-
tion of influenza and other respiratory infections), pri-
mary outcomes accounted for the largest proportion of
data items collected (50.3%), while in HIP (an EU-
funded trial of hypotension management in extremely
low gestational age newborns), safety data (21.1%) and
compliance data (21.1%) accounted for the largest pro-
portions of data items collected. Indeed, in ViDiFlu so
many data items were for primary outcomes (5096 or
78.1% of the overall total from all 18 trials) that their in-
clusion inflates the average proportion of primary out-
comes. These exceptions may relate to the nature of the
trials—for example, HIP involves newborns, which may
explain why it collected a lot of safety and compliance
data—or to the trials’ funding streams, which were dif-
ferent to the majority of trials in our sample, which were
largely funded by NIHR-Health Technology Assessment
(HTA) or the Chief Scientist Office of the Scottish
Government.
Table 4 summarises the categorisation results across
CTIMPs and non-CTIMPs separately. For CTIMPs, sec-
ondary outcomes (median 33.8%; mean 24.8%), safety
data (16.9%; 16.4%), regulatory data (11.5%; 11.7%) and
participant identification items (9.9%; 8.9%) constituted
the largest proportion of data items collected.
For non-CTIMPs, secondary outcomes (median 45.2%;
mean 46.0%), primary outcomes (5.5%; 10.8%), data
management outcomes (4.7%; 5.3%) and participant
identification items (4.5%; 4.0%) constituted the largest
amount of data items collected.
Non-outcome data accounted for the vast majority
(median 61.7%; mean 61.1%) of data items collected in
CTIMPs as compared with about a third (27.4%; 31.6%)
of data items collected in non-CTIMPs.
Discussion
General results
For our 18 trials a small proportion of all the data items
collected, a median of 5.0%, were for the primary out-
come assessment—the outcome assessment considered
by the trialists themselves to be of the highest import-
ance in their trial. The median of 5.0% is the better
measure due to one trial, ViDiFlu, devoting half of its
data items to the primary outcome.
Table 1 The 17 data collection categories
Category Example
Outcomes
1. Primary Outcome As identified in the trial protocol
2. Primary outcome but not primary analysis Primary outcome is weight loss at 12 months but weight loss is also measured at 3
months
3. Secondary Outcomes As designated in the trial protocol
4. Outcome data not listed as primary, secondary or health
economics outcome
5. Items from a core outcome set
6. Health Economics
Non-outcomes
7. Participant identification items Participant ID, postal contact details, general practitioner name and contact details
8. Items needed for randomisation Age, sex, site
9. Eligibility
10. Demographics Age, sex, family history of condition of interest
11. Medical History
12. Data Management Item Visit number
13. Safety Data Concomittant medications
14. Regulatory Data Deviation logging, reason for withdrawal
15. Compliance Data Dose administered, tablets taken or returned, confirmation of completed processes,
randomisation allocation
16. Process Outcomes How much blood was collected, who delivered the educational information
17. Miscellaneous
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Table 2 Characteristics of included categorised trials
Acronym Full title Funder Funding start –
end
(month/year)
Follow-
up
duration
Sample size Trial received
from
ActWELL A randomised controlled trial to assess the
impact of a lifestyle intervention (ActWELL) in
women invited to NHS breast screening
The Scottish
Government
Jan 2017 – Dec
2019
12
months
414 University of
Dundee
AMBER Abdominal massage for neurogenic bowel
dysfunction in people with multiple sclerosis
National Institute for
Health Research -
Health Technology
Assessment
(NIHR-HTA)
programme
July 2014 – June
2017
6 months 200 NMAHP
Research Unit,
Glasgow
Caledonian
University
CONFIDeNT CONtrol of Faecal Incontinence using Distal
NeuromodulaTion
NIHR-HTA Feb 2012 – Apr
2014
14 weeks 212 Queen Mary
University
London
EAGLE Whether removal of the lens of the eye (lens
extraction) for newly diagnosed primary angle
closure glaucoma results in better patient-
reported health vision, lower intraocular pres-
sure and other outcomes compared with stand-
ard management
NIHR - Efficacy and
Mechanism
Evaluation
(NIHR-EME)
Nov 2008 – July
2015
3 years 419 CHaRT,
University of
Aberdeen
ECLS Detection in blood of autoantibodies to tumour
antigens as a case-finding method in lung can-
cer using the EarlyCDT-Lung test
Chief Scientist Office,
Scottish
Government and
Oncimmune Ltd
Aug 2013 – Aug
2018
24
months
12,000 University of
Dundee
EMPiRE AntiEpileptic drug Monitoring in PREgnancy: an
evaluation of effectiveness, cost-effectiveness
and acceptability of monitoring strategies
NIHR-HTA Sept 2011 – Apr
2016
21 weeks
approx.
1000 Queen Mary
University
London
Acronym Full title Funder Funding start –
end
(month/year)
Follow-
up
duration
Sample size Trial received
from
HEALTH A multicentre randomised controlled trial
comparing laparoscopic supra-cervical hysterec-
tomy with second generation endometrial abla-
tion for the treatment of heavy menstrual
bleeding
NIHR-HTA Jan 2014 – Sep
2018
15
months
648 CHaRT,
University of
Aberdeen
HIP Management of Hypotension In the Preterm: a
multicentre, randomised controlled trial of
hypotension management in the extremely low
gestational age newborn
European
Commission within
the 7th Framework
Programme
Oct 2010 – Sep
2017
2 years 340 INFANT Centre,
Cork, Ireland
iQuaD A multicentre randomised controlled trial
comparing oral hygiene advice and periodontal
instrumentation for the prevention and
management of periodontal disease in dentate
adults attending dental primary care
NIHR-HTA Apr 2011 – Dec
2016
36
months
1860 University of
Dundee &
CHaRT,
University of
Aberdeen
KANECTa The use of ketamine as an anaesthetic during
electroconvulsive therapy (ECT) for depression:
does it improve treatment outcome?
Chief Scientist Office -
Scottish Government
Health Directorate
Apr 2011 – Apr
2014
1 month 40 CHaRT,
University of
Aberdeen
KAT Knee Arthroplasty Trial NIHR-HTA Dec 1998 –
June 2023
10–15
years
2450 CHaRT,
University of
Aberdeen
PIMS A randomised controlled trial comparing face-
down and face-forward positioning after eye
surgery for macular holes to see if this improves
the rate of macular hole closure
NIHR-HTA Apr 2015 – Apr
2018
3 months 192 Queen Mary
University
London
SALVO A Randomised Controlled Trial of Intra-
Operative Cell Salvage during Caesarean Sec-
tion in Women at Risk of Haemorrhage
NIHR-HTA Oct 2012 – Oct
2016
Until
discharge
3050 Queen Mary
University
London
Acronym Full Title Funder Funding start –
end
(Month/Year)
Follow-
up
Duration
Sample Size Trial Received
From
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Clearly the primary outcome is not the only thing
that is important. One outcome is unlikely to provide
all the information needed to make a judgement
about the treatment being tested, meaning secondary
outcomes are necessary. We also need to know
something about harms, as well as cost. Participant
identifiers and some data management and process
information will also always be needed. Trials may
also need to measure more than a single primary
outcome.
In our sample the median proportion of secondary
outcome data items is eight times that of the primary
outcome. The ratio of non-outcome data to primary out-
come data was similar. This might be fine. However, the
undeniable design importance of the primary outcome,
together with its importance to external judgements
about the utility of the intervention, makes this distribu-
tion of attention look odd. At a minimum it is worthy of
some reflection.
Our study raises three key questions:
1. Given that the primary outcome is the most
important and (likely) the only fully powered
outcome, is the substantially larger proportion of
data collected for secondary outcomes justified?
2. Do people really appreciate how much non-
outcome data trials collect?
3. Does volume of data correlate with data collection
effort?
Our study answers none of these questions. However,
it does highlight how important it is to try to answer
them. Data collection itself is hard work, and it generates
additional work by requiring data management systems,
quality assurance and, usually, data entry to deal with it.
Given the undoubted importance of the primary out-
come, we need to be sure that all outcomes in our set of
secondary outcomes—many, if not all, underpowered—
are worth the effort. If data collection effort does relate
to data volume, then it seems disproportionate for trial
teams to devote around eight times as much effort on
the secondary outcomes as on the primary. Secondary
outcomes may support understanding of the primary
outcome result, but they are not the outcomes that trial-
ists themselves consider to be of most importance. A
new Trial Forge project called ORINOCO (Optimising
Resource Use in Outcome Collection) will look at data
collection effort by collecting time spent collecting pri-
mary and secondary outcomes (https://www.abdn.ac.uk/
hsru/what-we-do/research/projects/orinoco-826.php).
Why trial teams collect so much data is unclear but,
anecdotally, we (and others) know that some investiga-
tors believe that since the participant is providing data
anyway, why not collect a few more things? The work
involved in doing this is unlikely to be borne by the per-
son making the request. Items unrelated to the original
aims of the trial are added, and trial team members have
their own interests, and each adds something to the data
collection job. Additional items can be added by Trial
Table 2 Characteristics of included categorised trials (Continued)
Acronym Full title Funder Funding start –
end
(month/year)
Follow-
up
duration
Sample size Trial received
from
SUSPENDa Use of drug therapy in the management of
symptomatic ureteric stones in hospitalised
adults: a multicentre placebo controlled
randomised trial of a calcium channel blocker
(nifedipine) and an α-blocker (tamsulosin)
NIHR-HTA Jun 2010 – Oct
2014
12 weeks 1200 CHaRT,
University of
Aberdeen
TAGS Treatment of Advanced Glaucoma Study
(TAGS): a multicentre randomised controlled
trial comparing primary medical treatment with
primary trabeculectomy for people with newly
diagnosed advanced glaucoma
NIHR-HTA Jan 2014 – Jan
2020 a(LTFU -
Dec 2023 not
included)
2 years 440 CHaRT,
University of
Aberdeen
TWICSa A randomised, double-blind placebo controlled
trial of the effectiveness of low dose oral theo-
phylline as an adjunct to inhaled corticosteroids
in preventing exacerbations of chronic obstruct-
ive pulmonary disease
NIHR-HTA July 2013 – Dec
2017
12
months
1424 CHaRT,
University of
Aberdeen
ViDiFlu Cluster-randomised, double-blind, placebo-
controlled trial of vitamin D supplementation
for the prevention of influenza and other re-
spiratory infections
NIHR - Programme
Grants for Applied
Research
Mar 2010 – Apr
2013 (LTP)
12
months
108 units, -
approx. 3
participants
per unit
Queen Mary
University
London
VUE Two parallel randomised controlled trials of
surgical options for upper compartment (vault
or uterine) pelvic organ prolapse
NIHR-HTA Nov 2012 – Jan
2018
12
months
800 CHaRT,
University of
Aberdeen
aCTIMP
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Steering Groups and, for that matter, funders. The ten-
dency always seems to be upwards when it comes to
data collection.
That said, our own anecdotal experience, and that of
others [16], is that when the going gets tough with out-
come collection, trial teams quickly start to focus on get-
ting just primary outcome data from participants. This
brings into stark focus the relative importance of those
secondary outcomes. Secondary outcomes can address
related questions and provide context in which to inter-
pret the primary outcome, but we need to keep their
relative importance in mind when selecting how many
of them to collect. For definitive Phase III trials such as
those we selected, a secondary outcome, like the pri-
mary, should be essential to the people (generally pa-
tients, healthcare professionals and policymakers) whose
decisions the trial is intended to support. Anything else
is garnish, which has clear resource implications in the
cash-limited world of publicly funded research.
The amount of non-outcome data was a surprise. That
a median of just under 5% of all data collected is linked
to the participant ID was not a result we expected, nor
was the finding that internal data management items
(e.g. ticking a box if a process was completed) was al-
most 6%. Some of this cannot be avoided, but even here
there is likely to be scope for efficiencies. For example,
the proportion of data items linked to demographics
ranged from 0 to 6.9%, with a median of 0.5%. Across
most of our trials, around 2% of data were demographic.
Trial designers should ask themselves at the beginning
of trials what a reasonable volume of demographic (or
other) data is, make sure they are resourced to collect at
that level and have a clear use for these data once
collected.
Our data underline that non-outcome data represent a
substantial proportion of the data that participants need
to provide and trial staff need to work with. Reducing
the burden of trials on participants and staff was
highlighted as an area in need of research to improve re-
tention by the PRIORITY-2 project [10], and ways of
assessing burden have been proposed [17]. One must
also carefully choose the non-outcome data that will be
collected so trial budgets and resource can be allocated
proportionately. Those making policy and governance
Table 3 Mean, min-max and median proportion values and total number of items for all 17 data categories across all trials
Proportions of data items within each trial were calculated and those proportions summarised across all 18 trials. Items above the dividing line are considered
outcome data, those under the line non-outcome data
aThe Health economics category was only used when these outcomes were not explicitly listed as a primary or secondary outcome
Crowley et al. Trials          (2020) 21:535 Page 7 of 10
decisions about research (e.g. sponsors, regulators) need
to weigh up their requirements for non-outcome data
against the work needed to collect and manage it. Al-
though we only included three CTIMPs, the impact of
regulation (or at least how regulation is interpreted) on
data collection workload is visible: for our three
CTIMPS a median of 11.5% of all data items collected
were classed as regulatory, compared to 1.9% for non-
CTIMPs. Regulatory decisions are capable of directly lead-
ing to thousands of extra items of data collection across
hundreds of trials. Regulators need to be confident that,
on balance, their requirements do more good than harm
and increase the transparency of their requirements. Grey
areas around what is needed to meet the conditions im-
posed can lead to over-collection of data, as researchers
may not be clear about what exactly is required. Some of
the potential harm is workload, particularly if conservative
interpretation, or misinterpretation, of legislation by re-
search administrators adds additional but unnecessary
data collection requirements [18].
Limitations and strengths
Our work has limitations. The 18 included trials were a
convenience sample rather than a random sample of
published trials. We quickly found that the categorisa-
tion process required someone close to each included
trial, and choosing trials that none of the team knew of
made categorisation difficult. As such, we do not claim
that our results are representative of all trials. However,
all the included trials are real trials, not hypothetical
ones, and they vary enormously in terms of trial teams,
intervention, sample size and follow-up durations. We
would be surprised if the headline result of substantially
more data items dedicated to secondary outcomes than
primary outcomes was overturned in a bigger sample.
Our categorisation method (see Additional file 1) can be
replicated by others for their own trials, and we could
perhaps build up a larger sample over time.
Only three CTIMPs were included in our sample,
which limits what we can say about a comparison be-
tween CTIMPs and non-CTIMPs. There appear to be
more regulatory and safety data collected in CTIMPs,
but to determine exactly how much requires rather more
CTIMP trials. Moreover, some regulators (e.g. the UK’s
Medicines and Healthcare products Regulatory Agency,
the MHRA) categorise CTIMPs by risk, which means
that not only would we need a larger sample, but also a
good mix of CTIMP risk categories.
The categories were not always exclusive, and much of
the discrepancy discussion between the reviewers cate-
gorising each trial amounted to which category won out
given that a case could be made for more than one. Our
SOP and guidance provided some rules. Generally, we
went with the emphasis given in the trial protocol for
outcomes and tried to be consistent for non-outcome
data. Different pairs of reviewers may have reached
slightly different conclusions for some items of data,
although we are confident that the process we used was
as robust as it could be for these judgement-based
decisions.
Table 4 Mean, min-max and median proportion values and total number of items for all categories across CTIMPs and non-CTIMPs
aTotals without ViDiFlu data
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There are some strengths too. The study idea came
from trial managers and addressed a question that was
very important to their trial front-line experience: what
sorts of data are collected in trials? We are confident of
the importance of the topic covered by this work. The
study also involved staff with diverse roles from seven
trials units in three regions with differing regulatory en-
vironments (England, Ireland and Scotland), which
brought a range of perspectives. We have created a set
of data categories, a SOP, guidance and some templates
(see Table 1 and Additional file 1) that others can now
use to assess their own trials, including at the design
stage. Finally, the project started some new collabora-
tions and has some simple messages that we think are
worth all trialists’ attention.
Implications for practice
1. For Phase III trials, we think trialists should
continue to consult with patients, health
professionals and policymakers to identify the
outcomes they will need to inform their future
decisions about the usefulness of the intervention
being tested. Trialists should then resist requests to
add to this list without having a compelling reason
for collecting data not essential to stakeholders’
future treatment decisions. Core outcome sets [19]
may help.
2. Trial teams could consider categorising the data
they propose collecting on their CRFs before they
start to use them. They could then check that the
distribution of data volume is what they anticipated
and want. This information would support
decision-making for resource allocation to collect,
process and quality control the data.
Implications for future research
1. Measuring data collection effort. The time actually
spent collecting data items is the focus of a new
Trial Forge data collection project: ORINOCO will
examine the time spent collecting primary and
secondary outcomes (https://www.abdn.ac.uk/hsru/
what-we-do/research/projects/orinoco-826.php).
2. Expansion of this work to assess a larger number of
trials potentially with a focus on CTIMPs, given the
small sample included here, would be beneficial.
3. The work described here did not assess whether
collected data were actually used, or published.
Doing so would be a useful addendum to this work,
perhaps along the lines of the study done by
O’Leary et al. [11].
4. The impact on data volume and distribution of
doing one or both items listed under ‘Implications
for practice’ would be worth evaluating. Like
anything else, they are only worth doing if they lead
to benefit. We would anticipate that they will
reduce both volume of data and number of
outcomes, especially secondary outcomes, but this
needs to be demonstrated.
Conclusion
Our results show that a small proportion of data col-
lected in the studied trials was related to the primary
outcome, while a substantial amount was not related to
trial outcomes. Generally speaking, secondary outcomes
account for eight times the volume of data as the pri-
mary outcome.
The data collection load is driven by the trial protocol.
It is important that those designing trials ensure that the
protocol focuses efforts on collecting data essential to
support the health and treatment decisions of those
whom the trial is designed to help. Collecting additional
data threatens the key purpose of the trial and may be
considered wasteful in the context of limited public
funding for clinical research.
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1186/s13063-020-04388-x.
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collected in trials
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